NCT03233347View on ClinicalTrials.gov

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

July 1, 2025

Study Completion Date

July 8, 2026

Conditions
Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaClassic Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

DRUG

Dacarbazine

Given IV

DRUG

Doxorubicin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

DRUG

Vinblastine

Given IV

Trial Locations (9)

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

37232

Vanderbilt University/Ingram Cancer Center, Nashville

55905

Mayo Clinic in Rochester, Rochester

68198

University of Nebraska Medical Center, Omaha

77030

M D Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

98195

University of Washington Medical Center - Montlake, Seattle

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER